Your browser is no longer supported. Please, upgrade your browser.
OncoCyte Corporation
Index- P/E- EPS (ttm)-0.41 Insider Own10.24% Shs Outstand91.45M Perf Week-19.63%
Market Cap179.24M Forward P/E- EPS next Y-0.46 Insider Trans0.00% Shs Float82.79M Perf Month-23.48%
Income-34.50M PEG- EPS next Q-0.13 Inst Own62.10% Short Float3.22% Perf Quarter-48.24%
Sales4.60M P/S38.96 EPS this Y-4.60% Inst Trans-0.73% Short Ratio5.11 Perf Half Y-64.73%
Book/sh1.09 P/B1.61 EPS next Y0.00% ROA-26.00% Target Price6.46 Perf Year-65.49%
Cash/sh0.43 P/C4.06 EPS next 5Y- ROE-40.40% 52W Range1.62 - 6.57 Perf YTD-18.89%
Dividend- P/FCF- EPS past 5Y-1.90% ROI-75.50% 52W High-72.27% Beta1.74
Dividend %- Quick Ratio3.60 Sales past 5Y- Gross Margin-30.00% 52W Low12.45% ATR0.20
Employees51 Current Ratio3.60 Sales Q/Q66.70% Oper. Margin- RSI (14)42.82 Volatility16.62% 9.53%
OptionableYes Debt/Eq0.02 EPS Q/Q-49.60% Profit Margin- Rel Volume0.54 Prev Close1.76
ShortableYes LT Debt/Eq0.00 EarningsNov 09 AMC Payout- Avg Volume521.75K Price1.82
Recom1.80 SMA20-8.51% SMA50-19.46% SMA200-53.27% Volume124,707 Change3.51%
Jan-07-22Initiated Stephens Overweight $3.10
Jan-06-22Resumed Piper Sandler Overweight $3.10
Mar-17-21Resumed Needham Buy $8
Jan-07-21Upgrade The Benchmark Company Speculative Buy → Buy $6
Dec-16-20Upgrade Piper Sandler Neutral → Overweight $2 → $4
Nov-30-20Initiated BTIG Research Buy $5
Nov-10-20Initiated KeyBanc Capital Markets Overweight $5
Jul-30-20Reiterated The Benchmark Company Speculative Buy $7 → $6
Jul-01-20Downgrade Piper Sandler Overweight → Neutral
Jun-30-20Downgrade Chardan Capital Markets Buy → Neutral $2
Jun-02-20Initiated Needham Buy $4
Feb-13-19Initiated Piper Jaffray Overweight $6
Jan-29-19Upgrade Janney Neutral → Buy
Dec-19-18Resumed Lake Street Buy
Jan-18-22 04:05PM  
Jan-06-22 09:43AM  
Jan-04-22 08:00AM  
Dec-09-21 06:00PM  
Dec-08-21 08:00AM  
Dec-06-21 08:00AM  
Dec-02-21 08:00AM  
Nov-22-21 06:14AM  
Nov-09-21 04:05PM  
Nov-04-21 08:00AM  
Nov-02-21 03:02PM  
Oct-27-21 08:00AM  
Oct-26-21 04:05PM  
Oct-08-21 09:46AM  
Oct-07-21 08:00AM  
Sep-30-21 08:00AM  
Sep-20-21 11:35AM  
Sep-16-21 08:00AM  
Sep-13-21 08:00AM  
Sep-07-21 04:05PM  
Aug-23-21 09:13AM  
Aug-18-21 08:49AM  
Aug-17-21 08:00AM  
Aug-10-21 04:01PM  
Aug-09-21 08:00AM  
Aug-03-21 03:00PM  
Jul-27-21 10:35AM  
Jul-08-21 05:34AM  
Jun-22-21 08:00AM  
Jun-15-21 08:03AM  
Jun-03-21 08:00AM  
Jun-01-21 08:00AM  
May-24-21 05:26AM  
May-17-21 04:01PM  
May-06-21 08:00AM  
May-04-21 04:01PM  
Apr-28-21 04:31PM  
Apr-19-21 08:00AM  
Apr-14-21 09:02AM  
Apr-10-21 01:31PM  
Apr-06-21 04:05PM  
Mar-23-21 01:44AM  
Mar-16-21 04:01PM  
Mar-15-21 08:00AM  
Mar-09-21 08:00AM  
Mar-04-21 08:00AM  
Mar-03-21 04:01PM  
Feb-25-21 08:00AM  
Feb-23-21 04:05PM  
Feb-16-21 04:05PM  
Feb-09-21 04:05PM  
Feb-05-21 06:06PM  
Feb-04-21 04:05PM  
Feb-02-21 09:35AM  
Jan-29-21 08:30PM  
Jan-28-21 08:00AM  
Jan-20-21 04:08PM  
Jan-12-21 06:21PM  
Dec-17-20 08:50AM  
Dec-15-20 10:48AM  
Dec-07-20 04:05PM  
Nov-30-20 05:38PM  
Nov-18-20 04:05PM  
Nov-17-20 11:55PM  
Nov-16-20 05:49AM  
Nov-12-20 04:05PM  
Nov-09-20 04:05PM  
Nov-05-20 11:23AM  
Nov-02-20 08:00AM  
Oct-28-20 08:00AM  
Oct-20-20 05:21PM  
Oct-14-20 08:00AM  
Oct-08-20 08:00AM  
Oct-01-20 08:00AM  
Sep-15-20 07:59AM  
Sep-14-20 08:00AM  
Sep-09-20 08:00AM  
Sep-03-20 08:00AM  
Sep-01-20 11:00AM  
Aug-27-20 08:00AM  
Aug-13-20 04:05PM  
Aug-11-20 08:00AM  
Aug-07-20 08:49AM  
Jul-29-20 06:45PM  
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides custom drug target discovery; assay design, development, and validation; and clinical trial and other testing services for pharmaceutical companies. OncoCyte Corporation has a strategic collaboration with Gruppo Oncologico del Nord-Ovest of Pisa to evaluate DetermaIO as a biomarker for immunotherapy response in metastatic colorectal cancer; and Echelon Diagnostics, Inc. The company was founded in 2009 and is headquartered in Irvine, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ANDREWS RONALD ASBURYChief Executive OfficerJul 01Option Exercise0.0065,0000259,046Jul 02 09:32 PM
ANDREWS RONALD ASBURYChief Executive OfficerMay 07Option Exercise0.00106,2210219,919Jul 02 01:59 PM
Levine Mitchell SChief Financial OfficerApr 28Option Exercise0.0020,000066,700Apr 30 07:09 PM
ANDREWS RONALD ASBURYChief Executive OfficerMar 19Buy4.7911,00052,702113,698Mar 22 05:17 PM
BROADWOOD PARTNERS, L.P.10% OwnerFeb 05Buy4.50600,0002,700,00016,776,484Feb 09 05:21 PM